Amylin Receptor Agonist and GLP-1 Receptor Agonist Combination Therapy

ChangeBridge: Patent Apps - Peptides (C07K)

Published April 2nd, 2026

Detected April 2nd, 2026

Summary

USPTO published patent application US20260091086A1 for a combination therapy comprising amylin receptor agonists and GLP-1 receptor agonists. The application, filed on May 19, 2025, covers polypeptide combinations for therapeutic uses including weight management (A61P 3/04). Invented by Sarah WILL, the application represents a potential new approach to metabolic disorder treatment.

View original document View source feed page

What changed

USPTO published patent application US20260091086A1 on April 2, 2026, covering a combination of amylin receptor agonists and GLP-1 receptor agonists. The application includes claims for therapeutic polypeptide combinations classified under A61K 38/26, A61K 38/22, and A61P 3/04, with CPC classifications C07K 14/575 and C07K 14/605. Application No. 19212361 was filed on May 19, 2025, by inventor Sarah WILL.

Pharmaceutical companies developing weight management or metabolic disorder treatments should review the application claims to assess potential freedom-to-operate implications or opportunities for licensing. Patent applications are published 18 months after filing; this publication represents an early-stage intellectual property claim rather than regulatory approval or market authorization.

Source document (simplified)

← USPTO Patent Applications

POLYPEPTIDE COMBINATIONS AND USES THEREOF

Application US20260091086A1 Kind: A1 Apr 02, 2026

Inventors

Sarah WILL

Abstract

The present invention relates to a combination of polypeptides and uses thereof. In particular, the present invention relates to a combination of an amylin receptor agonist and a GLP-1 receptor agonist, and uses thereof.